Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Are TKIs favourable for the elderly with non-small-cell lung cancer?

Oncotarget - 26 Jul 2016

Rossi Sabrina, D'Argento Ettore, Schinzari Giovanni, Dadduzio Vincenzo, Di Noia Vincenzo, Cassano Alessandra, Barone Carlo

Abstract excerpt

Background: Epidermal Growth Factor Receptor (EGFR) tyrosine-kinase inhibitors (TKIs) have changed treatment strategies for patients with advanced non-small-cell lung cancer (NSCLC) harbouring mutations in EGFR gene. This retrospective analysis assessed efficacy and safety of TKIs in elderly compared to younger patients. Patients and methods: 49 patients with advanced NSCLC and mutations in exon 19 or 21...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Quality of Life

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 27206674
DOI: 10.18632/oncotarget.9389
PMCID: PMC5216909

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Are TKIs favourable for the elderly with non-small-cell lung cancer?PMID 27206674Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer.Semantic proximity Read ↗

Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.Semantic proximity Read ↗

Clinical features and outcomes of first-line EGFR-TKI treatment in younger and older patients with EGFR-mutated NSCLC.Semantic proximity Read ↗

Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.Semantic proximity Read ↗

Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.Semantic proximity Read ↗

Recent advances in targeted advanced lung cancer therapy in the elderly.Semantic proximity Read ↗

Treatment outcomes in elderly with advanced-stage non-small cell lung cancer.Semantic proximity Read ↗

Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study.Semantic proximity Read ↗

First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.Semantic proximity Read ↗

Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.Semantic proximity Read ↗

Non-small cell lung cancer in the very young: Higher EGFR/ALK mutation proportion than the elder.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.